Literature DB >> 25764259

Paraneoplastic cerebellar ataxia associated with anti-Hu antibodies and benign ganglioneuroma.

Roberto Fancellu, Elena Corsini, Giorgio Bernardi, Paolo Buzzo, Maria Luisa Ferrari, Eleonora Lamantea, Alberto Garaventa, Mauro Truini, Sandro Salvarani.   

Abstract

We describe a case of cerebellar ataxia associated with anti-Hu antibodies and benign ganglioneuroma. A 28-year-old woman developed progressive ataxia with hyporeflexia at the age of 19. Brain MRI showed progressive cerebellar atrophy. Neurophysiological studies, screening of immune-mediated ataxias, oncological markers, vitamin E and genetic tests for spinocerebellar ataxia types 1,2,3, Friedreich ataxia and POLG1 were negative. Anti-Hu antibodies were positive in Western blot and indirect immunofluorescence (1:640). Total-body computed tomography revealed a mediastinum mass; the histological diagnosis was maturing ganglioneuroma. Immunohistochemistry showed a mild reaction between the tumor and the patient's serum, and no reaction between the tumor and control serum. After surgery, serum anti-Hu titer decreased, while ataxic symptoms initially worsened and then stabilized. Ganglioneuroma is a benign tumor, usually derived from the maturation of a neuroblastoma. The benign histology and the presence of anti-Hu antibodies could be related to the positive oncological prognosis and to the slow clinical course mimicking a degenerative ataxia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25764259      PMCID: PMC4370442     

Source DB:  PubMed          Journal:  Funct Neurol        ISSN: 0393-5264


  13 in total

1.  Maturation of sympathicoblastoma into ganglioneuroma; report of 2 patients with 20-and 46-year survivals respectively.

Authors:  F FOX; J DAVIDSON; L B THOMAS
Journal:  Cancer       Date:  1959 Jan-Feb       Impact factor: 6.860

2.  The Transformation of a Malignant Paravertebral Sympathicoblastoma into a Benign Ganglioneuroma.

Authors:  H Cushing; S B Wolbach
Journal:  Am J Pathol       Date:  1927-05       Impact factor: 4.307

3.  Favorable prognosis for survival in children with coincident opso-myoclonus and neuroblastoma.

Authors:  A J Altman; R L Baehner
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

4.  Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.

Authors:  H Shimada; I M Ambros; L P Dehner; J Hata; V V Joshi; B Roald
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

5.  Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases.

Authors:  Claudio Gambini; Massimo Conte; Gabriella Bernini; Paola Angelini; Andrea Pession; Paolo Paolucci; Alberto Donfrancesco; Edvige Veneselli; Katia Mazzocco; Gian Paolo Tonini; Lizzia Raffaghello; Carlo Dominici; Adriana Morando; Francesca Negri; Anna Favre; Bruno De Bernardi; Vito Pistoia
Journal:  Virchows Arch       Date:  2003-04-23       Impact factor: 4.064

6.  Scale for the assessment and rating of ataxia: development of a new clinical scale.

Authors:  T Schmitz-Hübsch; S Tezenas du Montcel; L Baliko; J Berciano; S Boesch; C Depondt; P Giunti; C Globas; J Infante; J-S Kang; B Kremer; C Mariotti; B Melegh; M Pandolfo; M Rakowicz; P Ribai; R Rola; L Schöls; S Szymanski; B P van de Warrenburg; A Dürr; T Klockgether; Roberto Fancellu
Journal:  Neurology       Date:  2006-06-13       Impact factor: 9.910

7.  Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97.

Authors:  Barbara Hero; Thorsten Simon; Ruediger Spitz; Karen Ernestus; Astrid K Gnekow; Hans-Guenther Scheel-Walter; Dirk Schwabe; Freimut H Schilling; Gabriele Benz-Bohm; Frank Berthold
Journal:  J Clin Oncol       Date:  2008-03-20       Impact factor: 44.544

Review 8.  Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment.

Authors:  D Haas; A R Ablin; C Miller; S Zoger; K K Matthay
Journal:  Cancer       Date:  1988-08-15       Impact factor: 6.860

9.  The association between neuroblastoma and opsoclonus-myoclonus syndrome: a historical review.

Authors:  Alexis B Rothenberg; Walter E Berdon; Giulio J D'Angio; Darrell J Yamashiro; Robert A Cowles
Journal:  Pediatr Radiol       Date:  2009-05-09

10.  Antineuronal antibody in a patient with neuroblastoma and opsoclonus-myoclonus-ataxia: a case report.

Authors:  A Salmaggi; R Nemni; A Pozzi; A Silvani; M G Forno; R Luksch; P Confalonieri; A Boiardi
Journal:  Tumori       Date:  1997 May-Jun
View more
  5 in total

1.  A rare cause of chronic ataxia in childhood: ganglioneuroma.

Authors:  Elif Acar Arslan; Tülay Kamaşak; Betül Diler Turgut; İsmail Saygın; Haluk Sarıhan; Ali Cansu
Journal:  World J Pediatr       Date:  2018-03-12       Impact factor: 2.764

Review 2.  Advances in Autoimmune Epilepsy Associated with Antibodies, Their Potential Pathogenic Molecular Mechanisms, and Current Recommended Immunotherapies.

Authors:  Zhiwei Fang; Yunqi Yang; Xuan Chen; Weiwang Zhang; Yangmei Xie; Yinghui Chen; Zhenguo Liu; Weien Yuan
Journal:  Front Immunol       Date:  2017-04-25       Impact factor: 7.561

3.  Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Nathan R McGee
Journal:  Front Neurol       Date:  2017-09-11       Impact factor: 4.003

4.  Ataxia as Forme Fruste of Opsoclonus Myoclonus Ataxia Syndrome.

Authors:  Sumeet R Dhawan; Indar Kumar Sharawat; Renu Suthar; Deepak Bansal; Prema Menon; Bishan D Radotra; Anmol Bhatia
Journal:  Ann Indian Acad Neurol       Date:  2020-06-10       Impact factor: 1.383

5.  Brain paraneoplastic syndromes in a patient with mediastinal ganglioneuroma.

Authors:  Jose Migue Escudero-Fernandez; Angel Sánchez-Montañez Garcia-Carpintero; Ignacio Delgado-Alvarez; Amparo Castellote-Alonso; Elida Josefa Vázquez-Mendez
Journal:  Radiol Case Rep       Date:  2020-09-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.